On November 4, 2019, RedHill announced that the U.S. Food and Drug Administration (FDA) had approved Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults.
RedHill expects to launch Talicia in the U.S. in the first quarter of 2020 with its dedicated sales force.
Each delayed-release capsule contains omeprazole 10 mg (equivalent to 10.3 mg omeprazole magnesium), amoxicillin 250 mg, and rifabutin 12.5 mg).
RELATED LINKS
Коментарі
Дописати коментар